Gilead Sciences Cash Flow Statement
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences free cash flow
In fiscal 2025, Gilead Sciences generated $10.02 billion of operating cash flow and spent $563.0 million on capital expenditures. That left free cash flow of $9.46 billion, a free-cash-flow margin of 32.1% of revenue. Free cash flow was down 8.2% from the prior year's $10.30 billion.
Gilead Sciences returned $5.92 billion to shareholders: $4.00 billion in dividends and $1.92 billion in share repurchases, equal to 63% of free cash flow. Free cash flow covered dividend payments 2.4 times.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 8.51B | 480.00M | 5.61B | 4.57B | 6.20B | 89.00M | 5.36B | 5.46B | 4.64B | 13.49B |
| Net Income growth (YoY) | +1672.92% | -91.45% | +22.93% | -26.37% | +6867.42% | -98.34% | -1.76% | +17.57% | -65.57% | -25.51% |
| Depreciation & Amortization | 370.00M | 381.00M | 354.00M | 323.00M | 329.00M | 288.00M | 255.00M | 226.00M | 233.00M | 177.00M |
| Stock-Based Compensation | 894.00M | 835.00M | 766.00M | 637.00M | 635.00M | 643.00M | 636.00M | 845.00M | 638.00M | 380.00M |
| Change in Working Capital | -1.84B | -148.00M | -535.00M | -1.40B | 850.00M | -860.00M | -1.07B | 520.00M | -389.00M | 232.00M |
| Operating Cash Flow | 10.02B | 10.83B | 8.01B | 9.07B | 11.38B | 8.17B | 9.14B | 8.40B | 11.90B | 17.05B |
| Capital Expenditures | -563.00M | -523.00M | -585.00M | -728.00M | -579.00M | -650.00M | -825.00M | -924.00M | -590.00M | -748.00M |
| Investing Cash Flow | -4.79B | -3.45B | -2.27B | -2.47B | -3.13B | -14.62B | -7.82B | 14.36B | -16.07B | -11.98B |
| Dividends Paid | -4.00B | -3.92B | -3.81B | -3.71B | -3.60B | -3.45B | -3.22B | -2.97B | -2.73B | -2.46B |
| Share Repurchases | -1.92B | -1.15B | -1.00B | -1.40B | -546.00M | -1.58B | -1.75B | -2.90B | -954.00M | -11.00B |
| Debt Issued | 0 | 3.46B | 1.98B | 0 | 0 | 8.18B | 0 | 0 | 8.98B | 5.29B |
| Debt Repaid | -1.79B | -1.97B | -2.25B | -1.50B | -4.75B | -2.50B | -2.75B | -6.25B | -1.81B | -1.98B |
| Financing Cash Flow | -7.75B | -3.43B | -5.13B | -6.47B | -8.88B | 770.00M | -7.63B | -12.32B | 3.39B | -9.72B |
| Net Change in Cash | -2.43B | 3.91B | 673.00M | 74.00M | -659.00M | -5.63B | -6.31B | 10.35B | -641.00M | -4.62B |
| Free Cash Flow | 9.46B | 10.30B | 7.42B | 8.34B | 10.80B | 7.52B | 8.32B | 7.48B | 11.31B | 16.30B |
This table shows 10 annual periods of Gilead Sciences's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a cash flow statement?